ChromaDex Corporation Reports 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
ChromaDex (CDXC) Misses Q4 EPS by 1c
March 10, 2021 4:26 PM ESTChromaDex (NASDAQ: CDXC) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $15.36 million.
Fourth Quarter 2020 and Recent Highlights
Total net sales of $15.4 million, up 18% from $13.1 million in the year ago quarter.Tru Niagen® net sales of $12.3 million, a 21% increase from the year ago quarter.Gross margin of 61.0%, a 400 basis point increase from the year ago quarter.Net loss was ($6.1) million or ($0.10) per share,... More